title: Update on the use of hydroxyurea therapy in sickle cell disease.
authors.affiliation: Division of Pediatric Hematology/Oncology and Department of Pathology, Oregon Health and Sciences University, Portland, OR;
authors.forename: Trisha E
authors.initials: TE
authors.lastname: Wong
authors.affiliation: Section of Pediatric Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI;
authors.forename: Amanda M
authors.initials: AM
authors.lastname: Brandow
authors.affiliation: Department of Medicine, Division of Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada; and.
authors.forename: Wendy
authors.initials: W
authors.lastname: Lim
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, FL.
authors.forename: Richard
authors.initials: R
authors.lastname: Lottenberg
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy* / Q000401:mortality; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000986:Antisickling Agents / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D006760:Hospitalization; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D008297:Male; D064887:Observational Studies as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D055815:Young Adult; D017086:beta-Thalassemia / Q000188:drug therapy
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000986:Antisickling Agents; D006918:Hydroxyurea